What does Elixir Ai do?

Elixir AI builds software to design, run and analyse paediatric clinical trials, reducing administrative burden for researchers.

Who founded Elixir Ai?

Elixir Ai was founded by Ed Cartwright, Agne Kazakeviciute in 2017.

Who are Elixir Ai's investors?

Elixir Ai's investors include Entrepreneur First.

Where is Elixir Ai headquartered?

Elixir Ai is headquartered in London, GB.

Elixir Ai

Entrepreneur First '17

London, GB · Founded 2017 · 2 employees on LinkedIn · 1 known investors

Find your way into Elixir Ai

Paths you didn't know you had: your email and LinkedIn already hold routes to the Elixir Ai team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Elixir AI makes software for running paediatric clinical trials, covering protocol authoring, digital recruitment and consent, remote data capture through online forms, and automated analysis of collected data. It is aimed at paediatricians and clinical researchers, with the goal of reducing the administrative work involved in a trial and shortening study timelines.

Also known as Elixir AI

Healthtech

Founders & leadership

Elixir Ai was founded in 2017 by Ed Cartwright and Agne Kazakeviciute.

Ed Cartwright Co-founder and CEOEd Cartwright is a paediatrician and genomic epidemiologist who completed his PhD at Cambridge, where he worked on MRSA whole genome sequencing with the Peacock lab and Wellcome Trust Sanger Institute. He is co-founder and CEO of Elixir AI and holds an Honorary Lecturer position at UCL Great Ormond Street Institute of Child Health in the Genomic and Pathogen Surveillance group.

Agne Kazakeviciute Co-founder & CTO2017–2019She brings over seven years of experience in finance, where she specialized in quantitative modeling, systematic trading strategies, and machine learning-based financial systems.

Investors · 1

Entrepreneur Firstlisted by Entrepreneur FirstBengaluru · $1M – $7M

How we know: the Entrepreneur First portfolio · open dataset · 5k.vc investor directory · Not right? Tell us

Company profile

researched Aug 2026

Elixir AI is a London-based software company, founded in 2017, focused on the operation of paediatric clinical trials. Its platform is intended to cover the trial lifecycle: authoring tools for protocol creation, digital recruitment and electronic consent, remote data capture via online forms, and automated analysis of the data collected. The stated aim is to cut the administrative workload associated with running a study and to shorten trial timelines.

No additional public reporting about this company was found among the source documents supplied. The searched material instead concerns unrelated entities that share the Elixir name — a wellness/"digital self" venture, a Solana-based token project for AI 3D-asset generation, a French light-aircraft manufacturer, and an India-based geospatial analytics firm — none of which relate to the paediatric clinical-trial software company covered here. Consequently, funding, traction, customer and headcount information could not be corroborated from the public sources available.

▸Full profile — market position, technology, go-to-market, geography, risks & controversies

Market position

Positioned within clinical trial technology, with a narrow focus on paediatric studies rather than general-purpose eClinical software. Public sources do not establish market share, customers or competitive standing.

Technology

Software platform combining protocol authoring tools, digital recruitment and consent workflows, remote electronic data capture through online forms, and AI-assisted analysis of trial data.

Go-to-market

Paediatricians and clinical researchers conducting trials in child health.

Geography

Headquartered in London, United Kingdom. No further locations are evidenced by available sources.

Risks & controversies

The company name overlaps with several unrelated organisations using the Elixir or Elixir AI name, which complicates public identification and verification. Publicly available documentation on the company itself is extremely limited, so funding status, commercial traction and current operating status remain unverified externally.

Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.

Companies House · registry record

View on Companies House ↗

Registered name: ELIXIR AI LIMITED
Company number: 10755261
Status: Active
Company type: Private limited company
Incorporated: 5 May 2017
Registered office: 7 Florence Gardens, Manningtree, CO11 2FB
Nature of business (SIC): 62012 — Business and domestic software development
Previous names: SENSUM TECHNOLOGIES LIMITED (2017–2018)
Accounts: last made up to 30 Mar 2025 · next due 30 Dec 2026
Confirmation statement: last made up to 4 Mar 2026 · next due 18 Mar 2027

Current officers · 2

Edward Cartwright — director, appointed 5 May 2017
Alexander James Palmer-Walsh — director, appointed 30 Mar 2020

Source: Companies House public register · retrieved 20 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

▸Research sources · 6

primary sources listed

ELIXIR AIelixirforever.com · web

6 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Elixir Ai do?: Elixir AI builds software to design, run and analyse paediatric clinical trials, reducing administrative burden for researchers.
Who founded Elixir Ai?: Elixir Ai was founded by Ed Cartwright, Agne Kazakeviciute in 2017.
Who are Elixir Ai's investors?: Elixir Ai's investors include Entrepreneur First.
Where is Elixir Ai headquartered?: Elixir Ai is headquartered in London, GB.